Logo image of BSX.DE

BOSTON SCIENTIFIC CORP (BSX.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:BSX - US1011371077 - Common Stock

76 EUR
-0.8 (-1.04%)
Last: 1/20/2026, 7:00:00 PM

BSX.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap112.67B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Shares1.48B
Float1.48B
52 Week High104
52 Week Low74.6
Yearly Dividend0
Dividend Yield0%
EPS(TTM)2.54
PE29.92
Fwd PE25.24
Earnings (Next)02-04
IPO1992-05-19
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
BSX.DE short term performance overview.The bars show the price performance of BSX.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

BSX.DE long term performance overview.The bars show the price performance of BSX.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 60 80

The current stock price of BSX.DE is 76 EUR. In the past month the price decreased by -3.06%. In the past year, price decreased by -21.65%.

BOSTON SCIENTIFIC CORP / BSX Daily stock chart

BSX.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BSX.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE. BSX.DE has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BSX.DE Financial Highlights

Over the last trailing twelve months BSX.DE reported a non-GAAP Earnings per Share(EPS) of 2.54. The EPS increased by 25% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.42%
ROA 6.54%
ROE 11.93%
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%19.05%
Sales Q2Q%20.34%
EPS 1Y (TTM)25%
Revenue 1Y (TTM)21.62%

BSX.DE Forecast & Estimates

40 analysts have analysed BSX.DE and the average price target is 108.94 EUR. This implies a price increase of 43.35% is expected in the next year compared to the current price of 76.

For the next year, analysts expect an EPS growth of 22.13% and a revenue growth 20.91% for BSX.DE


Analysts
Analysts85.5
Price Target108.94 (43.34%)
EPS Next Y22.13%
Revenue Next Year20.91%

BSX.DE Ownership

Ownership
Inst Owners94.07%
Ins Owners0.15%
Short Float %N/A
Short RatioN/A

BSX.DE Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
2M6.DE MEDTRONIC PLC 17.08 105.98B
1SHL.MI SIEMENS HEALTHINEERS AG 19.62 52.88B
SHL.DE SIEMENS HEALTHINEERS AG 18.63 50.22B
1PHIA.MI KONINKLIJKE PHILIPS NV 17.36 24.74B
PHIA.AS KONINKLIJKE PHILIPS NV 16.45 23.44B
PHI1.DE KONINKLIJKE PHILIPS NV 16.47 23.48B
BIM.PA BIOMERIEUX 26.84 12.26B
OBCK.DE OTTOBOCK SE & CO KGAA 138.3 4.16B
DIA.MI DIASORIN SPA 22.48 4.16B
1AFX.MI CARL ZEISS MEDITEC AG - BR 23.24 3.55B
AFX.DE CARL ZEISS MEDITEC AG - BR 22.02 3.17B
DRW3.DE DRAEGERWERK AG - PREF 13.57 1.64B

Related stock screener links

About BSX.DE

Company Profile

BSX logo image Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Company Info

BOSTON SCIENTIFIC CORP

300 Boston Scientific Way

Marlborough MASSACHUSETTS US

Employees: 53000

BSX Company Website

BSX Investor Relations

Phone: 15086834000

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What does BOSTON SCIENTIFIC CORP do?

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.


What is the current price of BSX stock?

The current stock price of BSX.DE is 76 EUR. The price decreased by -1.04% in the last trading session.


Does BOSTON SCIENTIFIC CORP pay dividends?

BSX.DE does not pay a dividend.


What is the ChartMill rating of BOSTON SCIENTIFIC CORP stock?

BSX.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the employee count for BSX stock?

BOSTON SCIENTIFIC CORP (BSX.DE) currently has 53000 employees.